Skip to content
FIND A BIOALPS ACTOR
Alithea Genomics

Alithea Genomics | Has been awarded CHF 150,000

04.05.2021
Share this article

CHF 150,000 for RNA sequencing to boost biomedical research

Lausanne-based Alithea Genomics, developing a novel technology that enables a high throughput library preparation for RNA sequencing, has been awarded CHF 150,000 from Venture Kick. The company will use the funds to advance and expand its BRB-seq kit offering.

A fundamental challenge of biomedical research today is to understand the cellular function. Whereas the genes, the DNA, are well documented, and gene sequencing has become a commodity, the expression of genes, the RNA, and their sequencing remains a major challenge. RNA sequencing (RNA-seq) technologies allow unbiased, high-content analyses of thousands of genes at once to accelerate the discovery of new drugs and biomarkers. However, the high cost of standard sample preparation for RNA-seq experiments restricts and prevents the use of gene expression analysis in studies involving large sample sets, such as high-throughput drug screening.

To address this technological limitation, Alithea Genomics has developed a proprietary sample preparation solution—called BRB-seq—that drastically decreases costs while increasing the throughput of RNA-seq. The startup’s technology enables projects that were previously unimaginable because they were too expensive and laborious. Alithea Genomics’ solutions provide R&D platforms with complete high-content actionable data, making biobank functionalisation and drug screenings efforts more feasible and efficient for insightful discoveries.

The freshly secured CHF 150,000 will flow into expanding its BRB-seq kit offering further and boost the revenues and services through dedicated marketing and sales activities. Moreover, part of the funds will be invested in the development of Alithea Genomics’ next-gen solution, which will bring throughput and cost-efficiency of RNA-seq to yet another new level.

More information